Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Tombal

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Acta Urologica Belgica|March 1, 1995
[Epipadiac duplication of the urethra]J Mostin, B Tombal, F Keupens, et al.
Scandinavian Journal of Urology|January 10, 2019
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonistE David Crawford, B Tombal, T Keane, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2013
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trialA Bahl, S Oudard, B Tombal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?J L Gala, S Loric, Y Guiot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancerA J Armstrong, P Lin, C S Higano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2014
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trialsR J van Soest, A J Templeton, F E Vera-Badillo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
Prostate Cancer and Prostatic Diseases|January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAILA H Bryce, J J Alumkal, A Armstrong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancerW Xie, P Ravi, M Buyse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trialA Jayaram, A Wingate, D Wetterskog, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Acta Urologica Belgica|March 1, 1995
[Epipadiac duplication of the urethra]J Mostin, B Tombal, F Keupens, et al.
Scandinavian Journal of Urology|January 10, 2019
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonistE David Crawford, B Tombal, T Keane, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2013
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trialA Bahl, S Oudard, B Tombal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?J L Gala, S Loric, Y Guiot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancerA J Armstrong, P Lin, C S Higano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2014
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trialsR J van Soest, A J Templeton, F E Vera-Badillo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
Prostate Cancer and Prostatic Diseases|January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAILA H Bryce, J J Alumkal, A Armstrong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancerW Xie, P Ravi, M Buyse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trialA Jayaram, A Wingate, D Wetterskog, et al.
Pageof 6